NY-ESO-1 Antibody [D2K7] | Primary Antibodies

Application: Reactivity: Human

Usage Information

Dilution
WB1:1000 IP1:100 IF1:1600 FCM1:400

Application
WB, IP, IF, FCM

Reactivity
Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
18 kDa 20 kDa (monomer), 40 kDa (dimer)
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
NY-ESO-1 Antibody [D2K7] detects endogenous levels of total NY-ESO-1 protein.

Clone
D2K7

Synonym(s)
Autoimmunogenic cancer/testis antigen NY-ESO-1, cancer antigen 3, CTAG, CTAG1, CTAG1A, CTAG1B, CTG1B, ESO1, L antigen family member 2, LAGE-2, LAGE2, LAGE2A, LAGE2B, New York esophageal squamous cell carcinoma 1, NY-ESO-1

Background
NY‑ESO‑1 is an X‑linked cancer–testis antigen that belongs to a family of germ cell–restricted proteins whose expression is largely confined to testis and ovary under physiological conditions and is absent from most normal somatic tissues while being re‑expressed in a broad spectrum of malignancies. The protein is a relatively small, non‑enzymatic, intracellular antigen with a central repetitive region and more conserved N‑ and C‑terminal portions that provide multiple peptide epitopes efficiently processed and presented by MHC class I and class II molecules, supporting robust CD8⁺ and CD4⁺ T‑cell recognition as well as antibody responses in cancer patients. NY‑ESO‑1 expression arises during fetal testis development and persists in adult germ cells, consistent with a role in gametogenesis, and in tumors its expression is tightly linked to DNA hypomethylation and chromatin changes at the CTAG1B locus, which convert a normally epigenetically silenced gene in somatic lineages into a tumor‑associated antigen. Within tumor cells, NY‑ESO‑1 localizes predominantly to the cytoplasm with variable nuclear staining, and its peptide fragments generated by the proteasome enter the endogenous antigen processing pathway and load onto HLA‑A, -B, or -C molecules, including well‑characterized epitopes such as HLA‑A*02:01–restricted NY‑ESO‑1 157–165, that are recognized by high‑affinity T‑cell receptors. Expression of NY‑ESO‑1 has been documented in a wide range of solid and hematologic tumors, including melanoma, non‑small cell lung carcinoma, ovarian cancer, synovial sarcoma, myxoid liposarcoma, multiple myeloma, and others, often with higher prevalence in advanced or poorly differentiated disease and with enrichment in particular histologic subtypes such as myxoid/round cell liposarcoma and myxoid soft tissue tumors. Tumor expression of NY‑ESO‑1 frequently coincides with spontaneous humoral and cellular immunity, with many patients exhibiting high‑titer NY‑ESO‑1–specific antibodies together with NY‑ESO‑1–specific CD8⁺ and CD4⁺ T cells, underscoring the strong intrinsic immunogenicity of this antigen and its capacity to break tolerance. NY‑ESO‑1 therefore functions as a prototypic target antigen for multiple immunotherapy platforms, including peptide vaccines, recombinant viral or protein vaccines, dendritic cell vaccines, and adoptive T‑cell therapies using TCR‑engineered or naturally expanded NY‑ESO‑1–specific T cells, where NY‑ESO‑1 provides both the tumor‑restricted antigenic determinant and, in some formulations, contributes adjuvant‑like properties through induction of strong helper and cytotoxic responses.

Background

NY‑ESO‑1 is an X‑linked cancer–testis antigen that belongs to a family of germ cell–restricted proteins whose expression is largely confined to testis and ovary under physiological conditions and is absent from most normal somatic tissues while being re‑expressed in a broad spectrum of malignancies. The protein is a relatively small, non‑enzymatic, intracellular antigen with a central repetitive region and more conserved N‑ and C‑terminal portions that provide multiple peptide epitopes efficiently processed and presented by MHC class I and class II molecules, supporting robust CD8⁺ and CD4⁺ T‑cell recognition as well as antibody responses in cancer patients. NY‑ESO‑1 expression arises during fetal testis development and persists in adult germ cells, consistent with a role in gametogenesis, and in tumors its expression is tightly linked to DNA hypomethylation and chromatin changes at the CTAG1B locus, which convert a normally epigenetically silenced gene in somatic lineages into a tumor‑associated antigen. Within tumor cells, NY‑ESO‑1 localizes predominantly to the cytoplasm with variable nuclear staining, and its peptide fragments generated by the proteasome enter the endogenous antigen processing pathway and load onto HLA‑A, -B, or -C molecules, including well‑characterized epitopes such as HLA‑A*02:01–restricted NY‑ESO‑1 157–165, that are recognized by high‑affinity T‑cell receptors. Expression of NY‑ESO‑1 has been documented in a wide range of solid and hematologic tumors, including melanoma, non‑small cell lung carcinoma, ovarian cancer, synovial sarcoma, myxoid liposarcoma, multiple myeloma, and others, often with higher prevalence in advanced or poorly differentiated disease and with enrichment in particular histologic subtypes such as myxoid/round cell liposarcoma and myxoid soft tissue tumors. Tumor expression of NY‑ESO‑1 frequently coincides with spontaneous humoral and cellular immunity, with many patients exhibiting high‑titer NY‑ESO‑1–specific antibodies together with NY‑ESO‑1–specific CD8⁺ and CD4⁺ T cells, underscoring the strong intrinsic immunogenicity of this antigen and its capacity to break tolerance. NY‑ESO‑1 therefore functions as a prototypic target antigen for multiple immunotherapy platforms, including peptide vaccines, recombinant viral or protein vaccines, dendritic cell vaccines, and adoptive T‑cell therapies using TCR‑engineered or naturally expanded NY‑ESO‑1–specific T cells, where NY‑ESO‑1 provides both the tumor‑restricted antigenic determinant and, in some formulations, contributes adjuvant‑like properties through induction of strong helper and cytotoxic responses.

References
https://pubmed.ncbi.nlm.nih.gov/29770138/ https://pubmed.ncbi.nlm.nih.gov/37857483/

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%